Black Duck Taps Protobrand Chairman and Founder Phil Granof as CMO

Black Duck Taps Protobrand Chairman and Founder Phil Granof as CMO

July 1, 2013

Open Source Software Management and Consulting Firm to Expand Brand Footprint

T2 Biosystems Announces New Data Correlating T2HemoStat(TM) Results to Clinical Outcomes in Cardiovascular Disease at ISTH

T2 Biosystems Announces New Data Correlating T2HemoStat(TM) Results to Clinical Outcomes in Cardiovascular Disease at ISTH

July 1, 2013

--Multiple Presentations Feature T2MR(R) for Rapid Characterization of Key Hematologic Factors and Novel Clot Biology Detection Directly from Whole Blood on a Single, Compact Instrument--

Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease

Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease

June 28, 2013

EBI-005 Met Endpoint and Efficacy Criteria in Phase 1b/2a Study

Eleven to Advance Clinical Development of EBI-005 for Dry Eye Disease and Other Ocular Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 28, 2013-- 

Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer

Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer

June 28, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 28, 2013-- 

Tangent Medical Announces U.S. Launch of the NovaCath™ Integrated IV Catheter System

Tangent Medical Announces U.S. Launch of the NovaCath™ Integrated IV Catheter System

June 27, 2013

ANN ARBOR, MI – Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, announced today its commercial product launch and start to clinical evaluations in several healthcare facilities across the U.S. The commercialization of this product is the first significant advancement in the IV catheter market in more than a decade.

Constructing Innovation Supply Chains for the Pharmaceutical Industry

Constructing Innovation Supply Chains for the Pharmaceutical Industry

June 26, 2013

Competition via innovation has been recognized as essential for mid- to long-term success and even survival of science-based corporations such as pharmaceutical and biotechnology companies. As such, understanding how best to innovate, and how to do it more often and efficiently, is top of mind for executives at many large corporations.

Affinnova Named to Honomichl Top 50 List for Third Consecutive Year

Affinnova Named to Honomichl Top 50 List for Third Consecutive Year

June 24, 2013

Marketing Technology Company Rises to No. 31, Up Seven Places from Previous Year

WALTHAM, Mass.--(BUSINESS WIRE)-- Affinnova, Inc., a global marketing technology company that dramatically improves innovation and marketing success rates, was recently named to the American Marketing Association’s Honomichl Top 50 for the third year in a row. Affinnova was listed at No. 31 and moved up seven spots from last year.

Flagship Ventures Kicks-off its VentureLabs™ Entrepreneurial Fellowship Program

Flagship Ventures Kicks-off its VentureLabs™ Entrepreneurial Fellowship Program

June 20, 2013

Fellows to embark on VentureLabs' unique exploration and venture creation process

CAMBRIDGE, Mass., June 20, 2013 /PRNewswire via COMTEX/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, announced the start of its fifth VentureLabs(TM) Entrepreneurial Fellowship Program, a unique opportunity for top graduate students to practice entrepreneuring in the pursuit of world changing venture opportunities.

Affinnova Launches Expansion to Asia

Affinnova Launches Expansion to Asia

June 17, 2013

Marketing-technology Company Opens First Asia Office in Singapore; Offices in India and China to Open within a Year

WALTHAM, MA, USA (June 17, 2013)Affinnova, Inc., a global marketing technology company that dramatically improves innovation and marketing success rates, today announced its expansion into Asia with a new office in Singapore and additional offices opening in India and China within a year.

Mascoma Announces FDA Favorable Review of its Next Generation Bioengineered Yeast, TransFerm® Yield+

Mascoma Announces FDA Favorable Review of its Next Generation Bioengineered Yeast, TransFerm® Yield+

June 18, 2013

– TransFerm Yield+ commercially available and commercial-scale trials in progress by corn ethanol producers –